Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

14.98 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcutis Biotherapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 Next >
Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Analyst Ratings for Arcutis Biotherapeutics
Via Benzinga
Analyst Expectations for Arcutis Biotherapeutics's Future
Via Benzinga
Why Shares of Arcutis Biotherapeutics Jumped This Week
The stock got a push when a British medical journal posted trials information on the company's lead product. 
Via The Motley Fool
Arcutis to Present at Upcoming Investor Conference
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
The Latest Analyst Ratings for Arcutis Biotherapeutics
Via Benzinga
Arcutis Biotherapeutics: Q1 Earnings Insights
Via Benzinga
Where Arcutis Biotherapeutics Stands With Analysts
Via Benzinga
Arcutis Biotherapeutics's Earnings Outlook
Via Benzinga
7 Short-Interest Stocks to Target for Explosive Gains
For contrarian investors that can stand the heat, short-interest stocks to buy can offer significant rewards in a short time period. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Completes Enrollment in INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Global Payments, MGM Resorts And 3 Stocks To Watch Heading Into Monday
With US stock futures trading slightly higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Arcutis Announces Canadian Approval of ZORYVE™ (roflumilast) Cream 0.3% for Treatment of Plaque Psoriasis in Individuals 12 Years and Older
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis to Report First Quarter Financial Results
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces New Coverage for ZORYVE® (Roflumilast) Cream 0.3% with National and Regional Health Plan Formularies, Bringing Total Commercial Covered Lives to Over 110 Million
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Presents Late-Breaking Data from the INTEGUMENT Phase 3 Trials in Atopic Dermatitis at American Academy of Dermatology Annual Meeting
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual Meeting
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis to Report Fourth Quarter 2022 Financial Results and Participate in Upcoming Investor Conference
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis' Flagship Psoriasis Treatment Shows Sustained Efficacy, Clearance For Median Of 10 Months
Via Benzinga
Arcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumilast Cream in Adults with Chronic Plaque Psoriasis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% for Expanded Indication for the Treatment of Plaque Psoriasis in Children Down to 2 Years of Age
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces Positive Topline Results from Second Atopic Dermatitis Pivotal Phase 3 Trial of Roflumilast Cream in Adults and Children Aged 6 and Older
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study Evaluating ARQ-255
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Study Showing Significant Improvements in Itch and Itch-Related Sleep Loss with Roflumilast Cream in Adults with Plaque Psoriasis Published in American Journal of Clinical Dermatology
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.